-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 27th, Betta released the third quarter report
.
In the first nine months, revenue was 1.
In terms of product sales, Icotinib achieved sales revenue of 1.
574 billion yuan in the first 9 months; Ensatinib achieved sales revenue of 65,301,700 yuan in the third quarter, and a total of 120 million yuan in sales in the first 9 months
.
In this year's medical insurance negotiations, the adjuvant treatment indications of icotinib and Ensatinib will participate in the negotiation, and it is expected that after entering the medical insurance, it will provide a boost to the growth of Betta
At the same time, Betta announced today that the Phase I/II clinical trial of the innovative drug project BTP-66M12 (MRX2843) has completed the first patient enrollment in the group
.
MRX2843 is a new, orally effective and potent dual inhibitor of Mer tyrosine kinase (MerTK) and FMS-like tyrosine kinase 3 (FLT3) for relapsed/refractory acute myeloid leukemia
According to the Insight database, Betta has launched six new drugs for the first time this year, including the imported PD-1 batilimumab and EGFR/c-Met dual anti-MCLA-129, and the self-developed fourth-generation EGFR inhibitor BPI -361175, PI3Kα inhibitor BPI-21668, KRASG12C inhibitor BPI-421286, and FGFR4 inhibitor BPI-43487; a new drug application for the third-generation EGFR inhibitor befortinib has also been submitted and is currently under review
